Ocular Cell Lines and Genotoxicity Assessment.
DNA damage
comet assay
epithelial cells
ocular cells lines
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
19 03 2020
19 03 2020
Historique:
received:
25
02
2020
revised:
10
03
2020
accepted:
16
03
2020
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
30
9
2020
Statut:
epublish
Résumé
Genotoxicity screening tests aim to evaluate if and to what extent a compound in contact with the human body (e.g., a drug molecule, a compound from the environment) interacts with DNA. The comet assay is a sensitive method used to predict the risk of DNA damage in individual cells, as it quantifies the tape breaks, being the alkaline version (pH > 13) the most commonly used in the laboratory. Epithelial cells serve as biomatrices in genotoxicity assessments. As ca. 80% of solid cancers are of epithelial origin, the quantification of the DNA damage upon exposure of epithelial cells to a drug or drug formulation becomes relevant. Comet assays run in epithelial cells also have clinical applications in human biomonitoring, which assesses whether and to what extent is the human body exposed to environmental genotoxic compounds and how such exposure changes over time. Ocular mucosa is particularly exposed to environmental assaults. This review summarizes the published data on the genotoxicity assessment in estimating DNA damage in epithelial cells with a special focus on ocular cell lines. General comet assay procedures for ex vivo and in vivo epithelium samples are also described.
Identifiants
pubmed: 32204489
pii: ijerph17062046
doi: 10.3390/ijerph17062046
pmc: PMC7142522
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Sci. 1993 Jan;104 ( Pt 1):37-49
pubmed: 8383696
Exp Eye Res. 1977 Jul;25(1):75-89
pubmed: 302215
Exp Eye Res. 1982 Aug;35(2):137-56
pubmed: 7151883
Regul Toxicol Pharmacol. 2014 Oct;70(1):87-97
pubmed: 24932799
Phytother Res. 2018 Nov;32(11):2202-2213
pubmed: 30080294
Int J Pharm. 2016 Sep 25;511(2):719-27
pubmed: 27480398
Nanotechnology. 2010 Jan 22;21(3):035102
pubmed: 19966402
Exp Cell Res. 1988 Mar;175(1):184-91
pubmed: 3345800
Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1387-98
pubmed: 9660487
Cancer Res. 1978 Sep;38(9):2827-35
pubmed: 679190
Curr Pharm Des. 2020;26(12):1235-1250
pubmed: 32067607
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093358
Curr Pharm Des. 2009;15(23):2724-50
pubmed: 19689343
Nucleic Acids Res. 1999 Feb 15;27(4):1070-8
pubmed: 9927741
Fundam Appl Toxicol. 1997 Apr;36(2):130-40
pubmed: 9143482
Cancer Res. 1997 Aug 15;57(16):3526-31
pubmed: 9270024
Molecules. 2020 Feb 06;25(3):
pubmed: 32041134
Mutat Res. 2000 Jun 22;468(1):11-7
pubmed: 10863153
Pharmaceutics. 2020 Feb 16;12(2):
pubmed: 32079103
Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3429-41
pubmed: 7693609
Mol Cell Endocrinol. 1984 Oct;37(3):319-29
pubmed: 6500171
Mutat Res. 2009 Mar 31;674(1-2):101-8
pubmed: 19041417
Eur J Pharm Biopharm. 2014 May;87(1):1-18
pubmed: 24530885
J Radiat Res. 2016 Jun;57(3):312-7
pubmed: 26951077
Expert Rev Clin Pharmacol. 2018 Jun;11(6):545-547
pubmed: 29667442
Mol Vis. 2011;17:3364-70
pubmed: 22219631
J Clin Pathol. 2020 Jan;73(1):51-56
pubmed: 31662438
Ophthalmic Res. 2014;51(3):124-8
pubmed: 24457594
Photochem Photobiol Sci. 2008 Feb;7(2):240-9
pubmed: 18264593
Photochem Photobiol. 2005 May-Jun;81(3):493-7
pubmed: 15773793
Cancer Res. 1977 Apr;37(4):1003-10
pubmed: 844036
Expert Rev Clin Pharmacol. 2019 Jan;12(1):1-7
pubmed: 30484336
Exp Eye Res. 1996 Feb;62(2):155-69
pubmed: 8698076
Mutat Res. 2011 Mar 18;721(1):27-73
pubmed: 21238603
Mol Oncol. 2014 Dec;8(8):1508-20
pubmed: 24994677
Curr Pharm Des. 2016;22(9):1135-46
pubmed: 26675225
J Appl Toxicol. 2014 Apr;34(4):395-403
pubmed: 24243595
Expert Opin Ther Pat. 2018 Dec;28(12):875-882
pubmed: 30484340
Pharmaceutics. 2019 Jul 24;11(8):
pubmed: 31344882
Acta Ophthalmol. 2013 May;91(3):219-25
pubmed: 22429721
Eye (Lond). 1994;8 ( Pt 2):170-83
pubmed: 7958018
Cont Lens Anterior Eye. 2019 Oct;42(5):512-519
pubmed: 30948195
Eur J Pharm Biopharm. 2017 Jan;110:58-69
pubmed: 27789359
Pharm Dev Technol. 2019 Dec;24(10):1243-1249
pubmed: 31437118
Mol Vis. 2011 Jan 05;17:1-6
pubmed: 21224996
Mutat Res. 1998 Jul 31;415(3):167-84
pubmed: 9714792
J Nanosci Nanotechnol. 2013 Jun;13(6):3769-77
pubmed: 23862406
Mol Biotechnol. 2004 Mar;26(3):249-61
pubmed: 15004294
Foods. 2017 Sep 05;6(9):
pubmed: 28872585
Acta Ophthalmol. 2013 Nov;91(7):652-6
pubmed: 22994213
Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1681-7
pubmed: 21842132
Front Genet. 2014 Nov 28;5:386
pubmed: 25506353
Eur J Pharm Biopharm. 2017 Jan;110:70-75
pubmed: 27789358
Mol Mar Biol Biotechnol. 1997 Dec;6(4):279-88
pubmed: 9418286
Biochem Biophys Res Commun. 1984 Aug 30;123(1):291-8
pubmed: 6477583
Mutat Res. 2011 Aug 16;723(2):121-8
pubmed: 20854927
In Vitro Cell Dev Biol. 1987 Feb;23(2):75-85
pubmed: 3102454
Methods Mol Biol. 1999;113:203-12
pubmed: 10443422
Molecules. 2019 May 17;24(10):
pubmed: 31109023
Mutat Res. 2003 Sep;544(1):43-64
pubmed: 12888107
Environ Mol Mutagen. 2000;35(3):206-21
pubmed: 10737956
Neuroreport. 2000 May 15;11(7):1571-9
pubmed: 10841379
Molecules. 2018 Jul 24;23(8):
pubmed: 30042375
Br J Clin Pharmacol. 2018 Apr;84(4):659-672
pubmed: 29433155
Invest Ophthalmol Vis Sci. 1994 Jun;35(7):3094-102
pubmed: 8206728
Int J Pharm. 2014 Jan 30;461(1-2):64-73
pubmed: 24275449